secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2024-02-06T23:59:59+00:00
Accession:  0001654954-24-001349
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

USPTO allows patent covering levosimendan use in PH-HFpEF through 2040
----------------------------------------------------------------------

- USPTO Notice of Allowance for patent covering oral (TNX-103), IV, subcutaneous levosimendan, active metabolites, and drug combos for PH-HFpEF.
- Once granted, patent provides IP protection until Dec 2040, may qualify for patent term extension beyond 2040.
- Third patent granted to Tenax since March 2023 protecting levosimendan for PH-HFpEF.
- Phase 3 LEVEL study (NCT05983250) ongoing: 152 patients randomized, primary endpoint 6-minute walk distance at Week 12.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495424001349/0001654954-24-001349-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495424001349/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-001349

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer